Source: International Congress 2019 – Pulmonary hypertension: new therapeutic pathways and modalities
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Montani (le Kremlin Bicêtre, France), B. Girerd (le Kremlin Bicêtre, France), X. Jais (le Kremlin Bicêtre, France), L. Savale (le Kremlin Bicêtre, France), P. Laveneziana (Paris, France), A. Bouchachi (le Kremlin Bicêtre, France), S. Hascoet (le Plessis Robinson, France), S. Gunther (le Kremlin Bicêtre, France), L. Godinas (le Kremlin Bicêtre, France), F. Parent (le Kremlin Bicêtre, France), C. Guignabert (le Kremlin Bicêtre, France), P. Herve (Le Plessis Robinson, France), G. Garcia (le Kremlin Bicêtre, France), G. Simonneau (le Kremlin Bicêtre, France), O. Sitbon (le Kremlin Bicêtre, France), M. Humbert (le Kremlin Bicêtre, France). Late Breaking Abstract - Screening of pulmonary arterial hypertension in asymptomatic BMPR2 mutation carriers (DELPHI-2 Study). 3951

Member's Comments

No comment yet.

Related content which might interest you: Screening of pulmonary arterial hypertension in BMPR2 mutation carriers Source: Virtual Congress 2020 – Genetics and genomics of pulmonary arterial hypertension Year: 2020 Late Breaking Abstract - Convergence of clinical and computational phenotypes for rare variant association study (RVAS) in pulmonary arterial hypertension Source: Virtual Congress 2021 – All about pulmonary arterial hypertension Year: 2021 Clinical manifestation of hereditary pulmonary arterial hypertension by a ²second hit² mutation in the genes BMPR2 and EIF2AK4 Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Molecular genetics and clinical features of Chinese idiopathic and heritable pulmonary arterial hypertension patients Source: Eur Respir J 2012; 39: 597-603 Year: 2012 Pulmonary arterial hypertension associated with several mutations Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Clinical phenotypes and outcomes of pulmonary veno-occlusive disease in carriers of bi-allelic EIF2AK4 mutations Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Mutational and epigenetic analysis of the promoter region of BMPR2 gene in patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Impact of treatment strategy in survival of patients with idiopathic pulmonary arterial hypertension. Real world evidence from Spanish National Pulmonary Hypertension Registry (REHAP) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Clinical characteristics, hemodynamics and survival in idiopathic and familial pulmonary arterial hypertension with germline BMPR2 mutation Source: Eur Respir J 2007; 30: Suppl. 51, 250s Year: 2007 Functional analysis of the 5´UTR region of BMPR2 gene in pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 LSC 2014 abstract - Combined effects of inflammatory mediators and BMPR2 mutation on pulmonary arterial cell function in a pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Absence of influence of gender on clinical phenotypes in BMPR2 mutation carriers with pulmonary arterial hypertension from the French registry Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Quality of life of patients with pulmonary arterial hypertension associated with congenital heart disease: The multicenter cross-sectional ACHILLE study Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation Source: Eur Respir J, 55 (5) 1902340; 10.1183/13993003.02340-2019 Year: 2020 Clinical outcomes of pulmonary arterial hypertension in carriers of ACVRL1 (ALK1) mutation Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Characteristics and outcomes of heritable pulmonary veno-occlusive disease due to EIF2AK4 mutations Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Analysis of BMPR2 gene expression in B-lymphocytes of pulmonary arterial hypertension patients Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Functional characterization of BMPR2 gene in pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015